Citigroup Corp. upgraded Fresenius (ETR:FRE) to Buy in a report released today.
- Updated: October 19, 2016
Just yesterday Fresenius (ETR:FRE) traded 0.00% even at 70.34EUR. Fresenius’s 50-day moving average is 41.00EUR and its 200-day moving average is 37.00EUR. The last stock price is up 0.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 0 shares of Fresenius exchanged hands, down from an avg. volume of 34,178
Citigroup Corp. has upgraded Fresenius (ETR:FRE) to Buy in a report released on 10/19/2016.
With a total market value of 0 EUR, Fresenius has with a one year low of 0.00EUR and a 52 week high of 52.00EUR .
About Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company's operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.